|

M108 monoclonal antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • FutureGen Biopharmaceutical (Beijing) Co., Ltd1

Indications

  • Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma1
  • Locally Advanced Unresectable or Metastatic Gastric Cancer1
  • Cancer1

Other1 trial

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.